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Use of Mouse Models to
Evaluate Novel Therapeutic
Approaches to Treatment of
Arrhythmogenic Right
Ventricular Cardiomyopathy
The Future Is Now*
Hugh Calkins, MD
Baltimore, Maryland
Arrhythmogenic right ventricular dysplasia (ARVD) is an
inherited cardiomyopathy that is characterized by ventricu-
lar arrhythmias, an increased risk of sudden death, and
abnormalities of right ventricular (RV) structure and func-
tion. The pathological hallmark of ARVD is myocyte loss
with fibro-fatty replacement. Since the first detailed clinical
description of the disorder in 1982, significant advances
have been made in our understanding of all aspects of this
disease (1–3). Particular focus has been placed on optimiz-
ing the approach to diagnosis of ARVD (4).Over the last
decade, mutations in several desmosomal proteins have been
identified as the genetic basis of ARVD (5–7). On the basis
See page 740
of these findings it is now recognized that ARVD is a
disease of desmosomal dysfunction (8). According to this
conceptual framework of ARVD, defective desmosomal
proteins lead to impaired mechanical coupling between
individual cells, resulting in myocyte detachment and de-
generation, especially under conditions that increase myo-
cardial strain. This leads to myocyte loss, replacement
fibrosis, and adiposis, with or without inflammation, which
might be nonspecific responses to myocyte injury. In addi-
tion to this mechanical mechanism of ARVD is a second
mechanism that results from the fact that some desmosomal
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desmosomal proteins might therefore also lead to dysregu-
lated gene expression. This conceptual framework of the
pathogenic basis of ARVD is welcomed, because it explains
many of the clinical observations that have been made in
patients with ARVD. These observations include a delayed
age of onset with subsequent progression as well as the
association between vigorous exercise and development of
ARVD. It also explains why the RV, which is more
distensible than the left ventricle due to its thinner wall and
asymmetric shape, is more often involved in ARVD. Fur-
thermore, defects in mechanical coupling of myocytes have
also been shown to lead to impairment in electrical cou-
pling. Ultrastructural evaluation of the myocardium of
patients with ARVD has shown reduced expression of
several intercalated disc proteins, including Connexin-43, a
key component of gap junctions (8,9). This finding might
account for the development of conduction delay and
arrhythmias, even in the absence of significant structural
defects in the early “concealed” phase of the disease.
Although there has been remarkable progress made con-
cerning the diagnosis of ARVD, the genetic basis of ARVD,
and the pathophysiologic basis of this disease, there has been
remarkably little research on 3 critical areas: 1) prevention of
disease development in susceptible individuals; 2) prevention of
progression and development of clinically manifest disease;
and 3) approaches to reverse ARVD in affected individuals.
The cornerstone of therapy for patients with ARVD at
present is placement of an implantable defibrillator for
prevention of sudden death and administration of antiar-
rhythmic agents and/or catheter ablation to decrease the
frequency of sustained ventricular arrhythmias (3,10).
In this issue of the Journal, Fabritz et al. (11) use a mouse
model of ARVD to test, for the first time, a novel load-
reducing therapeutic strategy for prevention of the develop-
ment of ARVD. The authors test their hypothesis in
heterozygous plakoglobin-deficient mice and wild-type lit-
termates who were subjected to 7 weeks of endurance
training (swimming). In a randomized and blinded study
design, mice were treated with load-reducing therapy (fu-
rosemide and nitrates) versus water. The mice were evalu-
ated with echocardiography and electrophysiology testing
with an isolated heart apparatus. In addition, the myocardial
tissue was evaluated with a number of basic techniques
including Western blots, immunohistology, and quantita-
tive polymerase chain reaction. The results of this study
revealed that load-reducing therapy prevented exercise-
induced RV enlargement. Furthermore, the rate of induc-
ibility of ventricular tachycardia was lower in heterozygous
mice who received load-reducing therapy as compared with
control subjects. In addition, the authors demonstrated that
RV longitudinal conduction velocity was reduced in un-
treated mice as compared with mice who received load-
reducing therapy.
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efforts to develop pharmacological, nonpharmacological,
and lifestyle strategies focused on prevention of disease
development in susceptible individuals, prevention of pro-
gression and development of clinically manifest disease, and
the development of approaches to reverse ARVD in affected
individuals. In writing this editorial, I am charged with
helping to interpret the results of this study in the context of
both my experience with ARVD as well as the considerable
body of previously published data on ARVD. It is important
to consider for a moment that there has never been a
prospective randomized clinical trial of any therapeutic
modality for treatment of patients at risk of or affected by
ARVD. This likely reflects both the rarity of this disease,
the heterogeneous nature of the patient population, the
often slow rate of disease progression, challenges with
obtaining funding for clinical trials in patients with ARVD,
as well as the reluctance of physicians and patients to
participate in prospective randomized clinical trials. Because
of these many obstacles, all forms of treatment of ARVD
are based mainly on empiric information, clinical experi-
ence, and expert opinion. Now we advise patients to
dramatically reduce their degree of exercise, and we prohibit
patients with ARVD from participating in competitive
sports. We also attempt to initiate beta-blocker therapy and
therapy with angiotensin-converting enzyme inhibitors. Fi-
nally, we advise implantable cardioverter-defibrillator inser-
tion in probands who meet diagnostic criteria for ARVD.
Pharmacological therapy and catheter ablation are used to
decrease the frequency of appropriate implantable cardioverter-
defibrillator therapies for ventricular tachycardia. The re-
sults of this study are striking, because to the best of my
knowledge, this is the first study that has tested a treatment
strategy for ARVD in a prospective and blinded trial. The
authors are to be congratulated for breaking this enormous
barrier and initiating what I hope will be a long series of
studies investigating potential treatment strategies for
ARVD. Our enthusiasm for this report needs to be tem-
pered somewhat, because it is clear that many questions
remain unanswered. Perhaps the most immediate question
is “Can the results of this study be applied to patients at risk
of development of ARVD or those with established
ARVD?” In my mind the answer is probably no. The
concept of treating patients who are susceptible to ARVD
or have established ARVD with a diuretic feels uncomfort-
able. These patients for the most part are not fluid-
overloaded, and I am concerned about the potential risks
associated with electrolyte depletion that might result from
diuretic use. Similarly, I would also find it uncomfortable to
start prescribing nitrates to patients with potential or estab-
lished ARVD. We are all well aware of the problems of
nitrate intolerance as well as the well-recognized side effects
of nitrate therapy. So for me, the implications of this study
are merely that I will now advise patients with ARVD to
decrease their salt intake. It is unfortunate that the authorsdid not select what I consider to be a clinically more viable
treatment strategy, especially beta-blockers and angiotensin-
converting enzyme inhibitors. These treatment strategies make
sense to me, as a clinician caring for patients with ARVD.
Other limitations include the small size of the study, the short
duration of follow-up, and the use of only 1 mouse and
genetic model of ARVD. It is also notable that this
particular mouse model of ARVD does not manifest the
hallmark clinical ARVD finding of fibro-fatty myocardial
replacement. Furthermore, this study did not address the
question of whether load-reducing therapy can reverse the
development of ARVD in mice with established disease.
Those involved in this field are grateful to Fabritz et al.
(11) for their considerable effort in performing and present-
ing the result of their novel study. I am sure that all of those
involved with the field of ARVD share my excitement that
this study has ushered in a new era of using mouse and other
animal models of ARVD to evaluate potential therapeutic
strategies for treatment of patients and families who suffer
from this condition.
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